高级检索
中华结核和呼吸杂志
期刊首页
过刊列表
高级检索
稿件发表
• 年度综述 •
ENGLISH ABSTRACT
支气管扩张症临床诊治与研究年度进展2024
姜瑞
姚安洁
王雨晴
萨依娜·阿布都克由木
郑慧珍
徐金富
作者及单位信息
·
DOI： 10.3760/cma.j.cn112147-20241121-00691
Annual review of bronchiectasis 2024
Jiang Rui
Yao Anjie
Wang Yuqing
Sayina Abudukeyoumu
Zheng Huizhen
Xu Jinfu
Authors Info & Affiliations
Jiang Rui
Department of Respiratory and Critical Care Medicine,Tongji University Affiliated Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, Shanghai 200433,China
Yao Anjie
Department of Respiratory and Critical Care Medicine,Tongji University Affiliated Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, Shanghai 200433,China
Wang Yuqing
Department of Respiratory and Critical Care Medicine,Tongji University Affiliated Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, Shanghai 200433,China
Sayina Abudukeyoumu
Department of Respiratory and Critical Care Medicine,Tongji University Affiliated Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, Shanghai 200433,China
Zheng Huizhen
Department of Respiratory and Critical Care Medicine,Tongji University Affiliated Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, Shanghai 200433,China
Xu Jinfu
Department of Respiratory and Critical Care Medicine,Huadong Hospital Affiliated to Fudan University, Shanghai 200040,China
·
DOI： 10.3760/cma.j.cn112147-20241121-00691
835
285
0
0
11
5
PDF下载
APP内阅读
摘要

支气管扩张症（简称支扩）是临床上常见的因各种病因导致的支气管异常和持久性扩张的慢性气道疾病。近一年来支扩领域取得了一系列重要进展，主要聚焦于流行病学、病原学、发病机制、合并症、治疗等方面。研究发现，痰液颜色、硝酸盐/亚硝酸盐可作为支扩急性加重的预后生物标志物，呼出气生物标志物的开发有利于筛查和诊断支扩，为支扩的防治靶点提供了新见解。此外，本年度支扩研究在治疗方面取得了较大进展，如二肽基肽酶1抑制剂、黏菌素干粉吸入剂、上皮钙通道阻滞剂等，推进了支扩精准治疗进程。新一代基因组测序技术的发展从遗传学、表观遗传学、转录组学和代谢组学等不同方面进一步探索了支扩的发病机制。综上，本文就2023年10月1日至2024年9月30日支扩领域的进展进行简要总结，以期对未来支扩研究方向提供新思路。

ABSTRACT

Bronchiectasis (BE) is a chronic airway disease characterized by bronchial abnormalities and persistent dilation due to a variety of underlying causes. Over the past year, significant advances have been made in the study of bronchiectasis, particularly in the areas of epidemiology, microbiology, pathogenesis, comorbidities, and treatment. Recent studies have identified sputum color and nitrate/nitrite levels as prognostic biomarkers for exacerbations, while advances in exhaled breath biomarkers have improved screening and diagnosis, providing new insights into preventive and therapeutic targets for bronchiectasis. Significant progress has also been made in therapeutic research, including the development of dipeptidyl peptidase-1 inhibitors, inhaled colistimethate sodium and epithelial calcium channel blockers, all of which are helping to the advancement of precision medicine in bronchiectasis. The development of new-generation genome sequencing technology can further explore the pathogenesis of bronchiectasis from various aspects including genetics, epigenetics, transcriptomics and metabolomics. In conclusion, this review provides a concise overview of the major advances in bronchiectasis research from October 1, 2023 to September 30, 2024, with the aim of providing new perspectives for future research directions.

Xu Jinfu, Email: mocdef.3ab61ncuxfj
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

姜瑞,姚安洁,王雨晴,等. 支气管扩张症临床诊治与研究年度进展2024[J]. 中华结核和呼吸杂志,2025,48(02)：158-163.

DOI:10.3760/cma.j.cn112147-20241121-00691

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

支气管扩张症（简称支扩）是一种临床常见的慢性气道疾病，是指各种病因导致的支气管异常和持久性扩张的一组异质性疾病，临床主要表现为慢性咳嗽、咳大量脓痰和（或）反复咯血 ［ 1 ］ 。近年来支扩的患病率已成为慢性气道疾病的第3位，在临床上也受到了更多的关注，出现了许多亟待解决的问题 ［ 2 ］ 。本文对2023年10月1日至2024年9月30日支扩领域发表的最新研究进行总结分析，阐述了支扩的流行病学、病原学、发病机制、合并症与危险因素、诊断与治疗等方面的新成果，以期对支扩有更新的认识与展望。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Polverino E , Goeminne PC , McDonnell MJ ,et al. European respiratory society guidelines for the management of adult bronchiectasis[J]. Eur Respir J, 2017,50(3):1700629. DOI: 10.1183/13993003.00629-2017 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Nigro M , Laska IF , Traversi L ,et al. Epidemiology of bronchiecta sis [J]. Eur Respir Rev, 2024,33(174):240091. DOI: 10.1183/16000617.0091-2024 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Xu JF , Zheng HZ , Lu HW ,et al. Baseline characteristics of patients in the Chinese bronchiectasis registry (BE-China): a multicentre prospective cohort study[J]. Lancet Respiratory Medicine. December. 2024
返回引文位置Google Scholar
百度学术
万方数据
[4]
Spinou A , Almagro M , Harris B ,et al. Diagnostic delay and access to care in bronchiectasis: data from the EMBARC/ELF patient survey[J]. Eur Respir J, 2024,64(1):2301504. DOI: 10.1183/13993003.01504-2023 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Spinou A , Hererro-Cortina B , Aliberti S ,et al. Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)[J]. Eur Respir J, 2024,63(6):2301689. DOI: 10.1183/13993003.01689-2023 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Chuang MH , Hsu W , Tsai YW ,et al. New-onset obstructive airway disease following COVID-19: a multicenter retrospective cohort study[J]. BMC Med, 2024,22(1):360. DOI: 10.1186/s12916-024-03589-4 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Mac Aogáin M , Dicker AJ , Mertsch P ,et al. Infection and the microbiome in bronchiectasis[J]. Eur Respir Rev, 2024,33(173):240038. DOI: 10.1183/16000617.0038-2024 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Duan JL , Li CY , Jiang Y ,et al. Microbiological characteristics of the lower airway in adults with bronchiectasis: a prospective cohort study[J]. Respir Res, 2024,25(1):283. DOI: 10.1186/s12931-024-02903-1 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Aksamit TR , Locantore N , Addrizzo-Harris D ,et al. Five-year outcomes among U.S. bronchiectasis and NTM research registry patient s [J]. Am J Respir Crit Care Med, 2024,210(1):108-118. DOI: 10.1164/rccm.202307-1165OC .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Song J , Sin S , Kang HR ,et al. Clinical impacts of Pseudomonas aeruginosa isolation in patients with bronchiectasis: findings from KMBARC registry[J]. J Clin Med, 2024,13(17):5011. DOI: 10.3390/jcm13175011 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
Harrington NE , Kottara A , Cagney K ,et al. Global genomic diversity of Pseudomonas aeruginosa in bronchiectasis[J]. J Infect, 2024,89(5):106275. DOI: 10.1016/j.jinf.2024.106275 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Dicker AJ , Lonergan M , Keir HR ,et al. The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study[J]. Lancet Respir Med, 2021,9(8):885-896. DOI: 10.1016/S2213-2600(20)30557-9 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Hibbert T M , Whiteley M , Renshaw S A ,et al. Emerging strategies to target virulence in Pseudomonas aeruginosa respiratory infections[J]. Crit Rev Microbiol, 2024,50(6):1037-1052. DOI: 10.1080/1040841x.2023.2285995 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Mac Aogáin M , Xaverius Ivan F , Jaggi TK ,et al. Airway "resistotypes" and clinical outcomes in bronchiectasis[J]. Am J Respir Crit Care Med, 2024,210(1):47-62. DOI: 10.1164/rccm.202306-1059OC .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Solarat B , Perea L , Faner R ,et al. Pathophysiology of chronic bronchial infection in bronchiectasis[J]. Arch Bronconeumol, 2023,59(2):101-108. DOI: 10.1016/j.arbres.2022.09.004 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Long MB , Chotirmall SH , Shteinberg M ,et al. Rethinking bronchiectasis as an inflammatory disease[J]. Lancet Respir Med, 2024,12(11):901-14. DOI: 10.1016/s2213-2600(24)00176-0 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Whitsett JA . Airway epithelial differentiation and mucociliary clearance[J]. Ann Am Thorac Soc, 2018,15(Suppl 3):S143-S148. DOI: 10.1513/AnnalsATS.201802-128AW .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Su Y , Zhang Y , Chai Y ,et al. Autoimmune diseases and their genetic link to bronchiectasis: insights from a genetic correlation and Mendelian randomization study[J]. Front Immunol, 2024,15:1343480. DOI: 10.3389/fimmu.2024.1343480 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Agarwal R , Sehgal IS , Muthu V ,et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses[J]. Eur Respir J,63(4):2400061. DOI: 10.1183/13993003.00061-2024 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Luo RG , Wu YF , Lu HW ,et al. Th2-skewed peripheral T-helper cells drive B-cells in allergic bronchopulmonary aspergillosis[J]. Eur Respir J, 2024,63(5):2400386. DOI: 10.1183/13993003.00386-2024 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Perea L , Faner R , Chalmers JD ,et al. Pathophysiology and genomics of bronchiectasis[J]. Eur Respir Rev, 2024,33(173). DOI: 10.1183/16000617.0055-2024 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Shteinberg M , Waterer G , Chotirmall SH . A Global effort to stop the vicious vortex: a special american journal of respiratory and critical care medicine issue for world bronchiectasis day 2024[J]. Am J Respir Crit Care Med, 2024,210(1):1-3. DOI: 10.1164/rccm.202405-0947ED .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Polverino E , Dimakou K , Traversi L ,et al. Bronchiectasis and asthma: data from the European bronchiectasis registry (EMBARC)[J]. J Allergy Clin Immunol, 2024,153(6):1553-1562. DOI: 10.1016/j.jaci.2024.01.027 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Ma D , Muñoz X , Ojanguren I ,et al. Increased TGFβ1, VEGF and IFN-γ in the sputum of severe asthma patients with bronchiectasis[J]. Arch Bronconeumol, 2024,60(11):682-689. DOI: 10.1016/j.arbres.2024.05.036 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Polverino E , De Soyza A , Dimakou K ,et al. The association between bronchiectasis and chronic obstructive pulmonary disease: data from the european bronchiectasis registry (EMBARC)[J]. Am J Respir Crit Care Med, 2024,210(1):119-127. DOI: 10.1164/rccm.202309-1614OC .
返回引文位置Google Scholar
百度学术
万方数据
[26]
He ZF , Lin SZ , Pan CX ,et al. The roles of bacteria and viruses in COPD-bronchiectasis association: a prospective cohort study[J]. Respir Med, 2024,231:107692. DOI: 10.1016/j.rmed.2024.107692 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Wang J , Chen X , He S ,et al. COPD assessment test and risk of readmission in patients with bronchiectasis: a prospective cohort study[J]. ERJ Open Res, 2024,10(2):00867-02023. DOI: 10.1183/23120541.00867-2023 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Méndez R , Feced L , Alcaraz-Serrano V ,et al. Cardiovascular events during and after bronchiectasis exacerbations and long-term mortality[J]. Chest, 2022,161(3):629-636. DOI: 10.1016/j.chest.2021.10.013 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Gao YH , Zhu YN , Bai JW ,et al. Severe pulmonary hypertension increased all-cause mortality in patients with bronchiectasis[J]. Arch Bronconeumol, 2024,60(7):454-457. DOI: 10.1016/j.arbres.2024.03.014 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
Gramegna A , Barone I , Alicandro G ,et al. The impact of cardiovascular events in bronchiectasis: a systematic review and meta-analysis[J]. ERJ Open Res, 2024,10(5):01032-02023. DOI: 10.1183/23120541.01032-2023 .
返回引文位置Google Scholar
百度学术
万方数据
[31]
Lo Casto M , Marino S , Zammuto MM ,et al. Patients with bronchiectasis have a lower combined risk of cardiovascular risk factors and cardiovascular comorbidity compared to patients with COPD[J]. Respir Med, 2024,229:107683. DOI: 10.1016/j.rmed.2024.107683 .
返回引文位置Google Scholar
百度学术
万方数据
[32]
Aliberti S , Ringshausen FC , Dhar R ,et al. Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European bronchiectasis registry (EMBARC)[J]. Eur Respir J, 2024,63(4):2301554. DOI: 10.1183/13993003.01554-2023 .
返回引文位置Google Scholar
百度学术
万方数据
[33]
Gao YH , Zheng HZ , Lu HW ,et al. Quality-of-life bronchiectasis respiratory symptom scale predicts the risk of exacerbations in adults with bronchiectasis: a prospective observational study[J]. Ann Am Thorac Soc, 2024,21(3):393-401. DOI: 10.1513/AnnalsATS.202302-133OC .
返回引文位置Google Scholar
百度学术
万方数据
[34]
Sun J , Tong X , Wang D ,et al. Multi-drug resistant Pseudomonas aeruginosa isolation is an independent risk factor for recurrent hemoptysis after bronchial artery embolization in patients with idiopathic bronchiectasis: a retrospective cohort study[J]. Respir Res, 2024,25(1):385. DOI: 10.1186/s12931-024-03019-2 .
返回引文位置Google Scholar
百度学术
万方数据
[35]
Chang CH , Chang CH , Huang SH ,et al. Epidemiology and outcomes of multidrug-resistant bacterial infection in non-cystic fibrosis bronchiectasis[J]. Ann Clin Microbiol Antimicrob, 2024,23(1):15. DOI: 10.1186/s12941-024-00675-6 .
返回引文位置Google Scholar
百度学术
万方数据
[36]
Zhou Y , He X , Tang J ,et al. Total sputum nitrate/nitrite is associated with exacerbations and Pseudomonas aeruginosa colonisation in bronchiectasis[J]. ERJ Open Res, 2024,10(4):01045- 02023 [pii ] . DOI: 10.1183/23120541.01045-2023 .
返回引文位置Google Scholar
百度学术
万方数据
[37]
Pollock J , Goeminne PC , Aliberti S ,et al. Aspergillus serologic findings and clinical outcomes in patients with bronchiectasis: data from the european bronchiectasis registry[J]. Chest, 2024:S0012-3692(24)05400- 05400X [pii ] . DOI: 10.1016/j.chest.2024.06.3843 .
返回引文位置Google Scholar
百度学术
万方数据
[38]
Kwok WC , Ho J , Tam T ,et al. Increased exacerbations of bronchiectasis following recovery from mild COVID-19 in patients with non-cystic fibrosis bronchiectasis[J]. Respirology, 2024,29(3):209-216. DOI: 10.1111/resp.14664 .
返回引文位置Google Scholar
百度学术
万方数据
[39]
Fan L , Chen Y , Chen Y ,et al. Discovery and analysis of the relationship between organic components in exhaled breath and bronchiectasis[J]. J Breath Res, 2024,19(1). DOI: 10.1088/1752-7163/ad7978 .
返回引文位置Google Scholar
百度学术
万方数据
[40]
Zhang LS , Wu YF , Lu HW ,et al. Fractional exhaled nitric oxide, a potential biomarker for evaluating glucocorticoids treatment and prognosis in allergic bronchopulmonary aspergillosis [J]. Ann Allergy Asthma Immunol, 2024,133(2):168-176.e1. DOI: 10.1016/j.anai.2024.05.010 .
返回引文位置Google Scholar
百度学术
万方数据
[41]
Cipolla D , Zhang J , Korkmaz B ,et al. Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial[J]. Respir Res, 2023,24(1):133. DOI: 10.1186/s12931-023-02444-z .
返回引文位置Google Scholar
百度学术
万方数据
[42]
Chalmers JD , Burgel PR , Daley CL ,et al. Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics[J]. ERJ Open Res, 2024,10(4):00151- 02024 [pii ] . DOI: 10.1183/23120541.00151-2024 .
返回引文位置Google Scholar
百度学术
万方数据
[43]
Chalmers JD , Gupta A , Chotirmall SH ,et al. A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf[J]. ERJ Open Res, 2023,9(3):00633- 02022 [pii ] . DOI: 10.1183/23120541.00633-2022 .
返回引文位置Google Scholar
百度学术
万方数据
[44]
Chalmers JD , Shteinberg M , Mall MA ,et al. Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF ® , a phase Ⅱ randomised, double-blind, placebo-controlled, dose-finding study [J]. Eur Respir J, 2024:2401551. DOI: 10.1183/13993003.01551-2024 .
返回引文位置Google Scholar
百度学术
万方数据
[45]
Haworth CS , Shteinberg M , Winthrop K ,et al. Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-Ⅰ and PROMIS-Ⅱ, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months[J]. Lancet Respir Med, 2024,12(10):787-798. DOI: 10.1016/S2213-2600(24)00225-X .
返回引文位置Google Scholar
百度学术
万方数据
[46]
Ringshausen FC , Shapiro AJ , Nielsen KG ,et al. Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial[J]. Lancet Respir M ed , 2024,12(1):21-33. DOI: 10.1016/S2213-2600(23)00226-6 .
返回引文位置Google Scholar
百度学术
万方数据
[47]
中国支气管扩张症临床诊治与研究联盟,中华医学会呼吸病学分会. 成人支气管扩张症病因学诊断专家共识[J]. 中华结核和呼吸杂志, 2024,47(10):921-932. DOI: 10.3760/cma.j.cn112147-20240606-00315 .
返回引文位置Google Scholar
百度学术
万方数据
[48]
Choi H , Xu JF , Chotirmall SH ,et al. Bronchiectasis in Asia: a review of current status and challenges[J]. Eur Respir Rev, 2024,33(173):240096. DOI: 10.1183/16000617.0096-2024 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
徐金富，Email： mocdef.3ab61ncuxfj
B
姜瑞, 姚安洁, 王雨晴, 等. 支气管扩张症临床诊治与研究年度进展2024[J]. 中华结核和呼吸杂志, 2025, 48(2): 158-163. DOI: 10.3760/cma.j.cn112147-20241121-00691.
C
所有作者声明无利益冲突
D
国家自然科学基金 (NSFC81925001，NSFC82330070)
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
中国心力衰竭诊断和治疗指南2024
中华医学会心血管病学分会 等
中华心血管病杂志 2024,52(03)
支气管扩张症研究年度进展2023
张黎莎 等
中华结核和呼吸杂志 2024,47(02)
肺癌流行病学研究年度进展2022
秦娜 等
中华医学杂志 2023,103(14)
支气管扩张症研究年度进展2022
郑慧珍 等
中华医学杂志 2023,103(08)
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大